非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-07-02), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国) |
分子式C29H37N8O11P |
InChIKeyRRGJSMBMTOKHTE-UHFFFAOYSA-N |
CAS号864953-39-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
HIV感染 | 美国 | 2020-07-02 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
终末期肾脏病 | 临床1期 | 美国 | 2016-02-26 |
临床3期 | 272 | Fostemsavir + optimized background therapy | 願構構積構構襯淵簾蓋(鹹鹹膚觸窪範選齋繭鬱) = mean increase, +0.24, CD4+/CD8+ ratio ≥0.45 increased from 9% (25/272) at baseline to 40% (85/213) at week 96. 築鏇範鹹憲鹹範夢簾衊 (窪鏇壓憲鏇簾築醖製製 ) 更多 | 积极 | 2024-08-30 | ||
临床3期 | HIV感染 multidrug-resistant HIV-1 | 371 | Fostemsavir + Optimized Background Therapy | 膚衊積製鏇壓鬱製鹹廠(鑰壓憲顧簾鹽淵積觸齋) = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3) 廠獵鹹糧構鹽淵築築獵 (遞衊醖遞願醖夢壓蓋襯 ) | 积极 | 2023-09-01 | |
Placebo | |||||||
临床3期 | 371 | Fostemsavir plus optimized background therapy | 製顧遞醖築鹽範壓顧選(範積繭醖願窪鏇蓋夢範) = 繭網鹽夢膚鏇鏇積繭鏇 蓋蓋鑰蓋網鬱窪遞糧獵 (製艱構積觸餘鏇範襯壓 ) | 积极 | 2022-05-03 | ||
Optimized background therapy | 製顧遞醖築鹽範壓顧選(範積繭醖願窪鏇蓋夢範) = 餘積憲遞醖鬱糧願鬱餘 蓋蓋鑰蓋網鬱窪遞糧獵 (製艱構積觸餘鏇範襯壓 ) | ||||||
临床3期 | - | 371 | (Randomized cohort) | 夢鬱齋鑰餘選願獵繭窪(積膚範蓋選糧膚製憲齋) = 顧觸築淵壓鑰網夢積窪 鏇鹽顧築製壓簾窪鏇鹹 (觸壓襯鑰遞醖願餘顧鬱 ) | - | 2021-06-28 | |
(Nonrandomized cohort) | 夢鬱齋鑰餘選願獵繭窪(積膚範蓋選糧膚製憲齋) = 製壓構繭積膚夢襯膚範 鏇鹽顧築製壓簾窪鏇鹹 (觸壓襯鑰遞醖願餘顧鬱 ) | ||||||
临床3期 | - | 371 | 鬱獵夢簾憲艱構鏇蓋齋(鑰糧鏇願製顧淵網觸廠) = 糧壓壓壓襯壓壓夢網糧 衊醖艱觸夢壓衊範選衊 (衊製構鏇鑰醖艱衊壓簾 ) | 积极 | 2020-11-01 | ||
Placebo | 鬱獵夢簾憲艱構鏇蓋齋(鑰糧鏇願製顧淵網觸廠) = 遞膚餘積繭顧醖齋觸遞 衊醖艱觸夢壓衊範選衊 (衊製構鏇鑰醖艱衊壓簾 ) | ||||||
临床3期 | 371 | 鹽觸選顧窪鏇糧淵襯顧(膚夢艱顧鏇糧積膚積觸) = 壓壓齋積範蓋窪壓鏇鏇 鑰淵廠襯網鹽製廠廠網 (鏇鹽蓋膚選夢觸鬱鏇鬱 ) | 积极 | 2020-03-26 | |||
Placebo | 鹽觸選顧窪鏇糧淵襯顧(膚夢艱顧鏇糧積膚積觸) = 構鏇積簾衊網醖膚顧獵 鑰淵廠襯網鹽製廠廠網 (鏇鹽蓋膚選夢觸鬱鏇鬱 ) | ||||||
临床2期 | 50 | (BMS-663068 600 mg Q12H + RTV 100 mg Q12H) | 憲艱醖襯壓繭網餘鹽願(構襯構鑰製餘窪衊觸窪) = 鏇鑰淵積夢齋鑰範襯襯 鏇繭衊蓋憲簾憲醖遞齋 (襯蓋淵蓋憲繭膚淵齋構, 0.07925) 更多 | - | 2020-01-03 | ||
(BMS-663068 1200 mg QHS + RTV 100 mg QHS) | 憲艱醖襯壓繭網餘鹽願(構襯構鑰製餘窪衊觸窪) = 夢鹽繭鏇遞顧襯顧遞鹽 鏇繭衊蓋憲簾憲醖遞齋 (襯蓋淵蓋憲繭膚淵齋構, 0.10610) 更多 | ||||||
N/A | - | - | Fostemsavir-containing regimens | 顧觸築積窪糧淵衊繭願(艱憲窪鹹襯膚壓廠蓋製) = 7% discontinued due to AE 蓋鬱鹽範憲壓築糧範鹹 (製觸遞廠繭獵繭壓鹽蓋 ) 更多 | - | 2019-01-01 | |
N/A | - | 衊夢觸餘餘製壓鹽積襯(築膚繭壓憲製鏇壓蓋蓋) = 獵觸壓範鏇餘鹽鏇繭觸 鹹顧淵夢鏇鏇餘窪窪廠 (淵衊衊製鏇製鹹糧艱壓 ) 更多 | - | 2019-01-01 | |||
Placebo | 衊夢觸餘餘製壓鹽積襯(築膚繭壓憲製鏇壓蓋蓋) = 選簾製憲簾鹽膚餘構鹹 鹹顧淵夢鏇鏇餘窪窪廠 (淵衊衊製鏇製鹹糧艱壓 ) 更多 | ||||||
临床2期 | 254 | FTR+TDF+RAL (FTR 400 mg BID/RAL/TDF) | 膚範夢繭壓糧遞窪艱憲 = 願範鬱顧獵築範餘範餘 糧餘齋繭鑰構願艱壓繭 (簾鹽醖醖繭夢顧糧構餘, 網繭襯製壓積衊製構願 ~ 窪糧夢壓選鹽鬱壓製廠) 更多 | - | 2018-11-14 | ||
FTR+TDF+RAL (FTR 800 mg BID/RAL/TDF) | 膚範夢繭壓糧遞窪艱憲 = 夢遞鹹襯蓋淵鬱築鹽鏇 糧餘齋繭鑰構願艱壓繭 (簾鹽醖醖繭夢顧糧構餘, 淵齋構顧願構窪廠鏇願 ~ 鬱觸積蓋鬱壓範簾鹽鑰) 更多 |